Screening methods for identifying ligands

Details Screening methods for identifying ligands Screening methods for identifying ligands

2005-09-27

2005-09-27

Moran, Marjorie A. (Department: 1631)

Data processing: measuring, calibrating, or testing

Measurement system in a specific environment

Chemical analysis

C435S006120, C435S007100, C117S011000

Reexamination Certificate

active

06950757

ABSTRACT:
This invention relates to crystallization based assays for identifying ligands that bind to a macromolecule.

REFERENCES:
patent: 5130105 (1992-07-01), Carter et al.
patent: 6039804 (2000-03-01), Kim et al.
patent: 6130227 (2000-10-01), Merlini et al.
patent: 6267935 (2001-07-01), Hol et al.
patent: 6297021 (2001-10-01), Nienaber et al.
patent: WO 99/45379 (1999-09-01), None
patent: WO 01/88113 (2001-11-01), None
Bernstein B., et al., “A bisubstrate analog induces unexpected conformational changes in phosphoglycerate kinase fromTrypanosoma brucei,” Journal of Molecular Biology, vol. 279, p. 1137-1148 (1998).
Bernstein B., et al., “Synergistic effects of substrate-induced conformational changes in phosphoglycerate kinase activation,”Nature, vol. 385 p. 275-278 (1997).
Brünger A, et al., “Crystallography and NMR systems (CNS) A new software system for macromolecular structure determination,”Acta Crystallographica, Section D, vol. D54, p. 905-921 (1998).
Burgin A., et al., “A novel suicide substrate for DNA topoisomerases and site-specific recombinases,”Nucleic Acids Research, vol. 23, p. 2973-2979 (1995).
Champoux J., “DNA Topoisomerases: structure, function, and mechanism,”Annual Reviews Biochem, vol. 70 p. 369-413, (2001).
Chen A., et al., “DNA topoisomerases: Essential enzymes and lethal targets,”Annu. Rev. Pharmacol. Toxicol, vol. 34, p. 191-218 (1994).
Hampton Research Solutions for Crystal Growth, Crystal Screen Reagent Formulations, listing PDF, 3pp, Downloaded from Hampton Research Website http://www.hamptonresearch.com/hrproducts/2110.html on World Wide Web URL: http://www.hamptonresearch.com/hrproducts/2110.html.
Hertzberg R., et al., “On the mechanism of topisomerase I inhibition by camptothecin: evidence for binding to an enzyme-DNA complex,”Biochemistry, vol. 28 p. 4629-4638 (1989).
Hsiang Y., et al., “Camptothecin induces protein-linked DNA breaks via mammalian DNA Topoisomerase I.”The Journal of Biological Chemistry, vol. 260, p. 14873-14878, (1985).
Huang H., et al., “Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance,”Science(1998), 282, p. 1669-1675.
Jia Z., et al., “Structure of protein tyrosine phosphatase 1B in complex with inhibitors bearing two phosphotyrosine mimetics,”Journal of Medicinal Chemistry, vol. 44, p. 4584-4594 (2001).
McRee D., “XtalView/Xfit—A Versatile Program for Manipulating Atomic Coordinates and Electron Density,”Journal of Structural Biology, vol. 125, p. 156-165 (1999).
Navaza J., “AMORE: a automated package for molecular replacement,”Acta. Crystallogrphica, vol. A50, p. 157-163 (1994).
Nitiss J., et al., “DNA topoisomerase-targeting antitumor drugs can be studied in yeast,”Proc. Natl. Acad. Sci. U.S.A., vol. 85, p. 7501-7505 (1988).
Redinbo M., et al., “Crystal structures of human topoisomerase l in covalent and noncovalent complexes with DNA,” Science, vol. 279, p. 1504-1513 (1998).
Scapin G., et al., “The structure of apo protein-tyrosine phosphatase 1B C215S mutant: more than just an S→ O change,”Protein Science, vol. 10, p. 1596-1605 (2001).
Stewart L., et al., “Reconstitution of human topoisomerase l by fragment complementation.”J Mol Biol, vol. 269, p. 355-372 (1997).
Stewart L., et al., “High-throughput crystallization and structure determination in drug discovery,”Drug Discovery Today, vol. 7, 187-196 (2002).
Stewart L., et al., “Biochemical and biophysical analyses of recombinant forms of human topoisomerase l,”The Journal of Biological Chemistry, vol. 271, p. 7593-7601 (1996).
Stewart L., et al., “A model for the mechanism of human topoisomerase l,”Science, vol. 279, p. 1534-1541 (1998).
Wall M., et al., “The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata,”Journal of the American Chemical Society, vol. 88, p. 3888-3890 (1966).

Affiliated with

Also associated with

Rating

Screening methods for identifying ligands does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Screening methods for identifying ligands, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Screening methods for identifying ligands will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3377326